Corium International Inc (NASDAQ:CORI)‘s stock had its “buy” rating reissued by stock analysts at Jefferies Group LLC in a report released on Friday. They currently have a $8.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 120.39% from the company’s previous close.

Several other equities analysts have also commented on CORI. Leerink Swann reissued a “buy” rating on shares of Corium International in a report on Wednesday, January 4th. Zacks Investment Research raised Corium International from a “sell” rating to a “hold” rating in a report on Thursday, February 16th. Needham & Company LLC dropped their price objective on Corium International from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, February 14th. FBR & Co set a $12.00 price objective on Corium International and gave the stock a “buy” rating in a report on Tuesday, February 14th. Finally, Cantor Fitzgerald set a $10.00 price objective on Corium International and gave the stock a “buy” rating in a report on Tuesday, February 14th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $10.21.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Corium International (NASDAQ:CORI) opened at 3.63 on Friday. Corium International has a one year low of $2.67 and a one year high of $8.33. The firm’s market cap is $106.08 million. The stock has a 50 day moving average price of $3.51 and a 200 day moving average price of $4.61.

Corium International (NASDAQ:CORI) last posted its earnings results on Monday, February 13th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by $0.04. The business earned $7 million during the quarter, compared to analysts’ expectations of $8.07 million. Corium International had a negative net margin of 116.26% and a negative return on equity of 359.24%. Equities research analysts expect that Corium International will post ($1.59) EPS for the current year.

Your IP Address:

An institutional investor recently raised its position in Corium International stock. RTW Investments LLC boosted its stake in Corium International Inc (NASDAQ:CORI) by 22.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,045,747 shares of the biopharmaceutical company’s stock after buying an additional 192,786 shares during the period. Corium International accounts for about 1.5% of RTW Investments LLC’s holdings, making the stock its 17th largest position. RTW Investments LLC owned 4.68% of Corium International worth $5,888,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 67.75% of the company’s stock.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

5 Day Chart for NASDAQ:CORI

Receive News & Ratings for Corium International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc and related companies with MarketBeat.com's FREE daily email newsletter.